+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

From
From
From
Atopic Dermatitis - Pipeline Insight, 2022 - Product Thumbnail Image

Atopic Dermatitis - Pipeline Insight, 2022

  • Clinical Trials
  • July 2022
  • 250 Pages
From
From
From
From
Global Parkinson's Disease Drugs Market 2018-2024 - Product Thumbnail Image

Global Parkinson's Disease Drugs Market 2018-2024

  • Report
  • March 2019
  • 110 Pages
From
From
From
From
Anti-Parkinson's Drugs: Global Markets to 2022 - Product Thumbnail Image

Anti-Parkinson's Drugs: Global Markets to 2022

  • Report
  • March 2018
  • 172 Pages
From
From
Rheumatoid Arthritis - Pipeline Insight, 2022 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2022

  • Clinical Trials
  • May 2022
  • 310 Pages
From
Systemic Lupus Erythematosus - Pipeline Insight, 2022 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Insight, 2022

  • Clinical Trials
  • May 2022
  • 250 Pages
From
Loading Indicator